Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Salarius Pharmaceuticals ( (SLRX) ) is now available.
Decoy Therapeutics, Inc. reported a significant financial downturn for the three and six months ended June 30, 2025, compared to the same periods in 2024. The company’s operating expenses decreased due to reduced research and development spending, but this was offset by a substantial increase in interest expenses and a decrease in grant income. The net loss for the three months ended June 30, 2025, was $1.8 million, a stark contrast to a net income of $1.1 million in the same period of 2024. Similarly, the net loss for the six months ended June 30, 2025, was $4 million, compared to $1.7 million in 2024. The company faces challenges in securing additional funding, which is critical for continuing its development programs and operations.
Spark’s Take on SLRX Stock
According to Spark, TipRanks’ AI Analyst, SLRX is a Underperform.
Salarius Pharmaceuticals exhibits significant financial instability, characterized by declining revenues and persistent losses, which severely impacts its stock score. Technically, the stock is on a bearish trend, trading below major moving averages, with negative momentum indicators. The valuation is further weakened by a negative P/E ratio and absence of dividend, making it unattractive to value or income investors. Overall, the stock is highly risky and requires cautious consideration.
To see Spark’s full report on SLRX stock, click here.
More about Salarius Pharmaceuticals
Average Trading Volume: 219,385
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.88M
For a thorough assessment of SLRX stock, go to TipRanks’ Stock Analysis page.